Ligand Pharmaceuticals LGND Financial Royalty Assets, Allowance
Segments
By product
See fullOther financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's financial royalty assets, allowance.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported financial royalty assets, allowance of $2.72M in Q1 2026.
- How has Ligand Pharmaceuticals's financial royalty assets, allowance changed year-over-year?
- Ligand Pharmaceuticals's financial royalty assets, allowance decreased by 15.3% year-over-year, from $3.21M to $2.72M.
- What is the long-term trend for Ligand Pharmaceuticals's financial royalty assets, allowance?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's financial royalty assets, allowance has grown at a -42.1% compound annual growth rate (CAGR), from $8.07M to $2.71M.